Kraj: Irlandia
Język: angielski
Źródło: HPRA (Health Products Regulatory Authority)
HERPES VIRUS STRAIN PB-THV 1 LIVE TURKEY
Intervet Ireland Limited
QI01AD
Pdr+Solv for Soln for Inj
Immunological - Live Vaccine
Fowl - Chicken
2003-12-17
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Nobilis Marek THV lyo 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active ingredients: VACCINE Per dose Turkey herpesvirus strain PB-THV-1 Minimum: 1000 pfu* The vaccine contains gentamycin as a remnant of production. For a full list of excipients see section 6.1. 3 PHARMACEUTICAL FORM Powder and solvent for solution for injection 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Chickens, from one day to three weeks of age. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For active immunisation of chickens to reduce clinical signs and/or lesions of virulent Marek’s Disease. Protection is seen by 8 days after vaccination. 4.3 CONTRAINDICATIONS Do not use in unhealthy birds. Sick or weak birds may not develop adequate immunity following vaccination. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 16/01/2007_ _CRN 7002913_ _page number: 1_ 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS The vaccine virus may spread to susceptible, unvaccinated birds. A good immune response is reliant on the reaction of an immunogenic agent and a fully competent immune system. Immunogenicity of the vaccine antigen will be reduced by poor storage or inappropriate administration. Immuno-competence of the animal may be compromised by a variety of factors including poor health, nutritional status, genetic factors, concurrent drug therapy and stress. Under certain conditions, for example extreme disease pressure, fully immune birds may succumb to disease. Therefore, successful vaccination may not be synonymous with full protection in the face of a disease challenge. Przeczytaj cały dokument